Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Jurgens EM, Mitra S, Herrera K, Nemirovsky D, Bready B, Derkach A, Hosszu K, McAvoy D, Firestone RS, Rajeeve S, Lesokhin AM, Korde N, Tan CR, Hashmi H, Hassoun H, Maclachlan K, Shah UA, Hultcrantz M, Merz M, Maura F, Giralt SA, Shah GL, Landau HJ, Scordo M, Kotchetkov IS, Santomasso BD, Park J, Leslie CS, Usmani SZ, Perica K, Mailankody S. Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma. Sci Transl Med. 2026 Jul 29; 18(860):eaed0039.
-
Pandey T, Samat D, Dahiya S, Patel SA. Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas. Front Immunol. 2026; 17:1900443.
-
Sotelo-Alva MI, Beyar-Katz O, Yan J, Escribano-Serrat S, Boardman A, Geva M, Gomez-Llobell M, Halloun J, Khatib H, Hultcrantz M, Lue J, Mailankody S, Papanicolaou G, Palomba L, Park JH, Rejeski K, Sanz J, Scordo M, Seo SK, Shah G, Shi K, Shibli N, Usmani S, Nishimura N, Shahid Z, Perales MA, Shouval R, Kamboj M, Einarsdottir S. Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort. Clin Infect Dis. 2026 04 30; 82(4):618-621.
-
Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson L, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK. Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. Blood Cancer J. 2026 04 14; 16(1).
-
Hashmi H, Sebastian T, Rajeeve S, Farzana T, Firestone RS, Jurgens EM, Miller KC, Maura F, Lesokhin AM, Tan CR, Shah GL, Korde N, Landau HJ, Merz M, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz ML, Derkach A, Nemirovsky D, Giralt S, Mailankody S, Usmani SZ. Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma. Blood Cancer J. 2026 04 12; 16(1).
-
Koumpouras F, Caricchio R. Cellular therapies for rheumatic disease. Curr Opin Rheumatol. 2026 May 01; 38(3):155-162.
-
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):369-378.
-
Raddatz MA, Stein-Merlob AF, Mahmood SS, Ganatra S, Addison D, Lin TL, Larson SM, Yang EH. Cardiotoxicity of T cell immunotherapies. Nat Rev Cardiol. 2026 Sep; 23(9):619-630.
-
Itoh-Nakadai A, Liang M, Shindo M, Bibi C, Tomizawa-Murasawa M, Fujiki S, Kaneko A, Kanamaru E, Hashimoto M, Kajita H, Ando Y, Kojima M, Moody J, Iwasaki M, Takagi S, Nakagawa R, Agrawal S, Amitani-Iijima H, Sato K, Sorimachi Y, Suzuki N, Fukami T, Hanada K, Morita S, Katsura K, Matsumoto T, Kobayashi M, Kato M, Negishi Y, Shirouzu M, Najima Y, Takubo K, Hon CC, Uchida N, Taniguchi S, Momozawa Y, Carninci P, Shultz LD, Saito Y, de Hoon M, Shin JW, Ishikawa F. CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting. Nat Commun. 2026 Jan 26; 17(1):101.
-
Maheswaran S, Gordon CD, Chen EC, Patel SA. Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia. Eur J Haematol. 2026 May; 116(5):501-511.